The ROE as of December 2024 (TTM) for Candel Therapeutics, Inc. (CADL) is 3.21%

According to Candel Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 3.21%. This represents a change of 18.72% compared to the average of 17.06% of the last 4 quarters.

Candel Therapeutics, Inc. (CADL) Historical ROE (quarterly & annually)

How has CADL ROE performed in the past?

The mean historical ROE of Candel Therapeutics, Inc. over the last ten years is -31.48%. The current 3.21% ROE has changed -10297.51% with respect to the historical average. Over the past ten years (40 quarters), CADL's ROE was at its highest in in the June 2024 quarter at 222.99%. The ROE was at its lowest in in the March 2024 quarter at -137.50%.

Candel Therapeutics, Inc. (CADL) ROE by Quarter and Year

Discovering the peaks and valleys of Candel Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Candel Therapeutics, Inc. (CADL) Average ROE

How has CADL ROE performed in the past?

The current ROE of Candel Therapeutics, Inc. (CADL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Candel Therapeutics, Inc. (CADL) ROE vs. Peers

How is CADL’s ROE compared to its peers?

Candel Therapeutics, Inc.’s ROE is greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Adagene Inc. (-50.10%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than Rezolute, Inc. (-69.83%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than Molecular Partners AG (-39.16%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Pharvaris N.V. (-38.27%), greater than PepGen Inc. (-60.17%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Acurx Pharmaceuticals, Inc. (-67679.28%), greater than Monopar Therapeutics Inc. (-21731.73%), greater than Enochian Biosciences, Inc. (-73.71%), greater than Indaptus Therapeutics, Inc. (-177.27%), greater than Tempest Therapeutics, Inc. (-187.44%), less than Comera Life Sciences Holdings, Inc. (67.46%), greater than Forte Biosciences, Inc. (-151.43%), greater than Bionomics Limited (-116.12%), greater than OKYO Pharma Limited (0.42%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Cingulate Inc. (-113174.53%),

Build a custom stock screener for Candel Therapeutics, Inc. (CADL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Candel Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Candel Therapeutics, Inc. (CADL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Candel Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.